IP Library Granted Patent US 12,178,912
Granted Patent B2
US 12,178,912 · App. 18/074,699 · Granted Dec 31, 2024

Twin-screw dry granulation for producing solid formulations

Inventors: Sampada Bhaskar Upadhye (Princeton, NJ); Ronald S. Vladyka (Somerset, NJ); Michael Andrew Repka (Oxford, MS); Jun-Bom Park (Seoul, KR); Roshan Vijay Tiwari (Hillsborough, NJ); Hemlata Gunga Patil (Hillsborough, NJ); Joseph Thomas Morott, Jr. (Morgantown, WV); Wenli Lu (Shanghai, CN)
Assignees: R.P. Scherer Technologies, LLC; UNIVERSITY OF MISSISSIPPI
A61K9/1682A61K9/0053A61K9/1635A61K9/1641A61K9/1647A61K9/1652A61K9/1694A61K9/2054A61K9/2095A61K31/4178A61K31/519B01J2/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,178,912
App. No.
18/074,699
Granted
Dec 31, 2024
Kind
B2
Abstract

A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.

Claims (11)

1. A granule comprising:

at least one active ingredient and at least one carrier having a melting point or a glass transition temperature lower than a melting point of the at least one active ingredient, wherein the granule has a surface area of about 0.05-0.45 m 2 /g and an angle of repose of less than or equal to about 30.

2. The granule of claim 1 , wherein the granule has a true density of about 1.15-1.35.

3. The granule of claim 1 , wherein the granule has a compressibility index of about 10-30.

4. The granule of claim 1 , wherein the granule has a Hausner ratio of less than about 1.25.

5. The granule of claim 1 , wherein the at least one active ingredient is selected from the group consisting of heat-sensitive active pharmaceutical ingredients, dehydration-sensitive active pharmaceutical ingredients, poorly-compressible active pharmaceutical ingredients, and high-dosage active pharmaceutical ingredients.

6. The granule of claim 1 , wherein the at least one carrier is selected from the group consisting of polysaccharides, povidones, acrylates, celluloses and polyols.

7. The granule of claim 1 , wherein the at least one carrier is selected from the group consisting of homopolymers and copolymers of N-vinyl pyrrolidone, copolymers of N-vinyl pyrrolidone and vinyl acetate or vinyl propionate; cellulose esters and cellulose ethers, hydroxyalkylcelluloses, hydroxyalkylalkylcelluloses, cellulose phthalates, cellulose succinates; polyethylene oxide, polypropylene oxide, copolymers of ethylene oxide and propylene oxide; polyacrylates, polymethacrylates, polyacrylamides; vinyl acetate polymers, polyvinyl alcohol, oligo- and polysaccharides and mixtures of one or more thereof.

8. The granule of claim 1 , wherein the at least one carrier is selected from the group consisting of hydroxylpropylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, methylcellulose, ethylhydroxyethylcellulose, hydroxyethylmethylcellulose, hydrophobically modified hydroxyethylcellulose, hydrophobically modified ethylhydroxyethylcellulose, carboxymethylhydroxyethylcellulose, and carboxymethyl hydrophobically modified hydroxyethylcellulose.

9. The granule of claim 1 , wherein the at least one carrier is a polymeric carrier having a molecular weight in a range of about 2,000-2,000,000 Daltons.

10. An oral dosage formulation comprising the granule of claim 1 , wherein the oral dosage formulation is a capsule, pellet, sachet, powder, or tablet.

Assignments (4)
SECURITY INTEREST Recorded Jun 17, 2025
From: ARDENA U.S. LLC
To: GLAS TRUST CORPORATION LIMITED, AS SECURITY AGENT
Reel/Frame 071429/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2025
From: R.P. SCHERER TECHNOLOGIES, LLC
To: ARDENA U.S. LLC
Reel/Frame 070769/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2023
From: UPADHYE, SAMPADA BHASKAR; VLADYKA, RONALD S., R.PH
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 064920/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2023
From: REPKA, MICHAEL ANDREW; PARK, JUN-BOM; TIWARI, ROSHAN VIJAY; PATIL, HEMLATA GUNGA; MOROTT, JOSEPH THOMAS, JR.; LU, WENLI
To: UNIVERSITY OF MISSISSIPPI
Reel/Frame 064920/0403 →
Continuity (4)
Continuation 16936008 · Jul 22, 2020
Division 15493568 · Apr 21, 2017
Provisional Application 62326046 · Apr 22, 2016
Related Publication 20230165799A1 · Jun 1, 2023